Research Article

Immune Responses to RHAMM in Patients with Acute Myeloid Leukemia after Chemotherapy and Allogeneic Stem Cell Transplantation

Figure 4

RHAMM-specific CTLs are present, but not functional. PBMCs were obtained from an AML patient who received chemotherapy. (a), (b). RHAMM-specific CTLs detected by flow cytometry at the stage of smoldering leukemia (c)–(f) and at the stage of progressive disease (g)–(j) did not release neither IFN-γ (a), nor granzyme B (b) at a level higher than background (no peptide control) as assessed by ELISPOT assays. (c)–(j) Reported frequencies correspond to all cells in the CD3+CD8+ T-cell gate (upper numbers), and to all cells in the lymphocyte gate (lower numbers). (c), (g) Isotype negative control, (d), (h) Non-peptide negative control, stained with an irrelevant tetramer, (e), (i) Non-peptide negative control, stained with RHAMM tetramer, (f), (j) CD8+ T cells were stimulated with RHAMM peptide and stained with RHAMM tetramer.
146463.fig.004a
(a)
146463.fig.004b
(b)
146463.fig.004c
(c)
146463.fig.004d
(d)
146463.fig.004e
(e)
146463.fig.004f
(f)
146463.fig.004g
(g)
146463.fig.004h
(h)
146463.fig.004i
(i)
146463.fig.004j
(j)